[Research progress in the adjunct therapy of recurrent respiratory papillomatosis].

Recurrent respiratory papillomatosis （RRP） is a benign tumor of the respiratory tract caused by human papillomavirus （HPV） infection. At present, there is no cure for this disease, and mainly depends on surgical resection to relieve symptoms but cannot prevent recurrence. Multiple surgeries will bring heavy mental and economic burdens to patients and their families. Therefore, researchers are constantly seeking new treatments to reduce the number of operations and prevent recurrence. Hence, research on adjuvant therapy drugs has also been widely carried out, including bevacizumab, cidofovir, HPV vaccine, and Chinese medicine as an adjuvant drug according some reports. This article reviews the adjuvant treatment of RRP in recent years.